Skip to main content
. Author manuscript; available in PMC: 2013 May 25.
Published in final edited form as: Clin Trials. 2012 Apr 30;10(1 0):S5–S36. doi: 10.1177/1740774512440342

Table 3.

Sensitivity of the sample size to assumptions concerning the rate of nonfatal SNA events as a proportion of the rate of fatal serious non-AIDS events and the proportion of events accepted by the Endpoint Review Committee

Ratio: nonfatal SNA to fatal SNA % AIDS* events accepted by the ERC Composite primary event rate per 100 person-years (deferred arm) Hazard ratio (average over follow-up) Sample size Expected number of events
3 65 2.40 0.706 4,244 351
4 65 2.81 0.712 3,822 369
5 65 3.23 0.717 3.472 383
3 75 2.49 0.700 3,900 333
4 75 2.91 0.707 3,545 353
5 75 3.33 0.712 3,245 367

AIDS: acquired immunodeficiency syndrome; SNA: serious non-AIDS.